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Due to the low number of collectable stem cells from single umbilical cord blood (UCB) unit, their initial uses were limited to 
pediatric therapies. Clinical applications of UCB hematopoietic stem and progenitor cells (HSPCs) would become feasible if 
there were a culture method that can effectively expand HSPCs while maintaining their self-renewal capacity. In recent years, 
numerous attempts have been made to expand human UCB HSPCs in vitro. In this study, we report that caffeic acid phenethyl 
ester (CAPE), a small molecule from honeybee extract, can promote in vitro expansion of HSPCs. Treatment with CAPE in-
creased the percentage of HSPCs in cultured mononuclear cells. Importantly, culture of CD34+ HSPCs with CAPE resulted in a 
significant increase in total colony-forming units and high proliferative potential colony-forming units. Burst-forming 
unit-erythroid was the mostly affected colony type, which increased more than 3.7-fold in 1 μg mL1 CAPE treatment group 
when compared to the controls. CAPE appears to induce HSPC expansion by upregulating the expression of SCF and HIF1-α. 
Our data suggest that CAPE may become a potent medium supplement for in vitro HSPC expansion. 
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Transplantation of hematopoietic stem cells and progenitor 
cells (HSPCs) has been used for many years to treat various 
malignant and non-malignant hematologic diseases. The 
infused HSPCs can replace and reconstitute the hematopoi-
etic and immune systems in patients subjected to chemo-
therapy or radiotherapy. In the last decade, umbilical cord 
blood (UCB) becomes a new resource of HSPCs for al-
logeneic transplantation [1]. UCB transplantation shows 
many advantages, including elimination of donor risk, rapid 
availability, low risk of infection, and preservation of 
graft-versus-leukemia effect, despite the relatively low risk 
of graft-versus-host disease. Due to the low number of col-
lectable stem cells from single UCB units, the initial uses 
were limited to pediatric therapies. Clinical applications of 
UCB HSPCs would become feasible if there were a culture 
method that can effectively expand HSPCs while maintain-
ing their self-renewal capacity.  
In recent years, numerous attempts have been made to 
expand human UCB HSPCs in vitro [2,3]. Most ex vivo 
cultures of human HSPCs use cytokine mixtures in se-
rum-free medium that includes SCF, TPO, IL-3, IL-6 and 
Flt3-L [4]. The manipulation of some signaling pathways 
such as Notch and Wnt has also shown effectiveness for ex 
vivo expansion of HSPCs [5]. Several labs explored to ex-
pand HSPCs with aryl hydrocarbon receptors, copper che-
lators, stromal support, and automated continuous perfusion 
of culture systems or “bioreactors” [3,68]. Over-expres- 
sion of transcription factors, such as SALL4, HOXB4, can 
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also increase the number of HSPCs in vitro [9,10]. Alt-
hough in vitro culture method for expansion of HSPCs has 
been improved, it still needs to be optimized to obtain more 
transplantable HSPCs. 
Caffeic acid phenethyl ester (CAPE) is an active compo-
nent of propolis from honeybee with various beneficial 
properties, such as anti-inflammatory and antioxidant ef-
fects [11]. Increasing evidence suggests that CAPE can ex-
ert protective effect against ischemia/reperfusion (I/R) inju-
ry occurred in many tissues [1214]. Wang has reported 
that CAPE treatment induced the upregulation of kit ligand 
(SCF) and heme oxygenase-1 (HO-1) gene expression in 
HUVECs [15]. Both SCF and HO-1 play important roles in 
the regulation of HSPC function [16]. Thus, we speculate 
that CAPE may also play a role in the in vitro proliferation 
of HSPCs. 
In this study, we report that CAPE, a small molecule 
from honeybee extract, can promote in vitro UCB HSPC 
expansion, and CAPE induces HSPC expansion probably 
through upregulating the expression of SCF and HIF1-α. 
Our data suggest that CAPE may become a potent medium 
supplement for in vitro HSPC expansion. 
1  Materials and methods 
1.1  The isolation of MNCs and CD34+ cells  
MNCs were isolated from the fresh UCB samples using 
lymphocyte separation medium in 1.077 g mL1 (TBD sci-
ences, China). The cell suspension was centrifuged at 600×g 
for 25 min, and then MNCs band at the interface was iso-
lated, and washed twice with PBS (Gibco, USA). The 
CD34+ cells were isolated from MNCs using the CD34+ 
Microbead kit (MiltenyiBiotec, Germany) according to the 
manufacturer’s protocol. 
1.2  In vitro culture  
The CD34+ cells (2×105 cells/well) or MNCs (1×106 
cells/well) were cultured in 24-well plates (Costar tis-
sue-culture treated polystyrene, Corning, USA) in HSPC 
expansion medium (StemSpan SFEM, StemCell Technolo-
gies, Canada). The medium was supplemented with several 
cytokines (Peprotech, USA), including SCF (25 ng mL1), 
TPO (10 ng mL1), IL-3 (20 ng mL1), IL-6 (10 ng mL1). 
CAPE was added into the culture medium at different con-
centrations (0.1 μg mL1, 1 μg mL1). Cells were cultured at 
37°C in 5% CO2. 
1.3  Flow cytometry 
Cells were washed twice in PBS containing 2% FBS. The 
cells were incubated with isotypic antibodies or the indicat-
ed antibodies in the dark for 40 min at 4°C. Next, the cells 
were washed three times with PBS and suspended in 0.4 mL 
PBS for analysis. Live cells were determined by 7-AAD 
(BD Biosciences, USA) exclusion. Flow cytometry analysis 
was performed using BD FACS Aria (BD Biosciences). The 
data were analyzed using BD FACSDiva software. The fol-
lowing antibodies were used: CD34-PE (eBioscience, USA), 
CD38-APC (eBioscience). 
1.4  Cell apoptosis and survival analysis 
The CD34+ cells were washed in PBS and apoptosis was 
evaluated as the percentage of Annexin V-positive cells 
using apoptosis kit (Invitrogen, USA) according to the 
manufacturer’s protocol. 
1.5  Colony-forming units (CFU) assay 
Cultured CD34+ cells (5×102 cells/well) or MNCs (4×103 
cells/well) at day 7 were plated in a methylcellulose-based 
medium (MethoCult H4434, StemCell Technologies). Each 
experiment was performed in triplicate. Two weeks after 
plating, CFU were counted under an inverted microscope 
and identified according to morphological criteria. High 
proliferative potential colony-forming units (HPP-CFU) 
were counted at three weeks after plating. 
1.6  Quantitative RT-PCR 
Cells were lysed and total RNA was isolated by Trizol Re-
agent (Invitrogen), followed by reverse transcription of 1 μg 
total RNA with the reverse transcriptase M-MLV (Takara, 
Japan) using oligo(dT) primers. Quantitative RT-PCR reac-
tions were performed with SYBR Green real time PCR 
Master Mix (TOYOBO, Japan) on Bio-Rad iQ5 System 
(Bio-Rad, USA). The expression of each gene was normal-
ized to GAPDH gene expression and three replicates were 
analyzed for each condition. The primer sequences for 
quantitative RT-PCR were listed in Supporting Infromation 
(Table S1 in Supporting Information). 
1.7  Statistic analysis 
All values were shown as mean±SD. The statistic signifi-
cance between two groups was determined by Student’s 
t-test. 
2  Results 
2.1  Treatment with CAPE increases the percentage of 
HSPCs  
To evaluate whether CAPE (Figure 1A) has the capability 
to expand HSPCs, we isolated UCB-derived MNCs and 
placed them in medium with cytokines alone or cytokines 
plus 0.1 or 1 μg mL1 CAPE for 7 d. The increase in total 
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Figure 1  A, The structure of CAPE. B, The total cell numbers of MNCs 
growing at different CAPE concentrations for 7 d. 
cell numbers was not significantly different between the 
cytokines alone or cytokines plus 1 μg mL1 CAPE group 
(Figure 1B). Then we used flow cytometer to analyze the 
percentage of HSPCs in cultured cells. The percentage of 
CD34+ and CD34+CD38 cells was approximately 1.5% and 
0.2% in primary UCB MNCs (Figure 2Aa). Both cytokines 
and cytokines plus CAPE treatments induced significant 
increase of the proportion of HSPCs in cultured MNCs 
(Figure 2Ab–d). Much higher percentage of CD34+ or 
CD34+CD38 cells was observed in cultures treated with 
cytokines plus 1 μg mL1 CAPE (Figure 2Ad). The numbers 
of CD34+ or CD34+CD38 cells also increased in cultured 
 
Figure 2  The detection of CD34+ and CD34+CD38 cells in cultured MNCs at different CAPE concentrations. A, The percentage of CD34+ and 
CD34+CD38 cells in primary MNCs (a, 0 d; just separated from cord blood) and MNCs cultured for 7 d (bd, with different CAPE concentrations). B, The 
CD34+ cell numbers were calculated in the cultured MNCs with CAPE treatment at different concentrations. C, The CD34+CD38 cell numbers were calcu-
lated in the cultured MNCs with CAPE treatment at different concentrations. **, P0.01 vs. 0 μg mL1. 
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MNCs with cytokines plus 1μg mL1 CAPE (Figure 2B and 
C). These data indicated that treatment with CAPE promot-
ed the in vitro expansion of UCB HSPCs. 
2.2  Treatment with CAPE increases the numbers of 
CFU 
To further evaluate the effect of CAPE on HSPC prolifera-
tion, we isolated UCB CD34+ cells using miniMACS selec-
tion system and cultured them with cytokines alone or cyto-
kines plus CAPE for 7 d. Compared with control group, the 
survival rate of these cultured CD34+ cells was not signifi-
cantly altered with CAPE treatment at 0.1 μg mL1 and 
showed a slight decrease with CAPE treatment at 1 μg mL1 
(Figure 3). However, the content of hematopoietic progeni-
tor cells was significantly increased with CAPE treatment. 
In CFU assays (Figure 4A), culture of CD34+ cells with 0.1 
or 1 μg mL1 CAPE resulted in a dose-dependent increase in 
burst-forming unit-erythroid (BFU-E) and colony forming 
unit-granulocyte, erythrocyte, megakaryocyte, macrophage 
(CFU-GEMM) (Figure 4B). Interestingly, BFU-E was the 
most affected colony type, increasing more than 3.7-fold in 
cells treated with 1 μg mL1 CAPE when comparing to the 
control group (Figure 4B). For total CFU, a 2.6-fold or 
3.1-fold increase in 0.1 or 1 μg mL1 CAPE-treated cells 
was observed when compared with the control group (Fig-
ure 4C). The numbers of HPP-CFU were also markedly 
increased with CAPE treatment (Figure 4D). 
2.3  CAPE upregulates the expression of SCF and 
HIF-1α 
To investigate the mechanism by which CAPE increased the 
numbers of HSPC, we performed Q-PCR analysis to detect 
the expression of proliferation and apoptosis-related genes 
with cDNA from cultured MNCs. Wang has reported that 
CAPE treatment induced the upregulation of kit ligand 
(SCF) and HO-1 in HUVECs [15]. SCF plays a critical role  
for early phases of hematopoiesis, and facilitates HSPC 
proliferation and survival [16]. Our results showed that 
CAPE significantly upregulated the expression of SCF. The 
increased secretion of SCF protein was also observed in 
CAPE-treated cells (data not shown). HO-1 is a critical reg-
ulator of the stress response in HSPCs via controlling the 
level of its substrates (heme) and bioactive products [17]. 
The expression of HO-1 was also significantly upregulated 
by CAPE. Hypoxia-inducible factor-1α (HIF-1α) is required 
for long-term HSC maintenance and can synergize with 
glucocorticoids to promote BFU-E progenitor self-renewal 
[18,19]. We also found that the expression level of HIF-1α 
was increased by CAPE treatment. In addition, there was a 
slight increase in the expression of BCL-2 gene in the cells 
treated with 1 μg mL1 CAPE. These results suggested that 
increased expression of SCF and HIF-1α promoted the ex-
pansion of HSPCs. 
3  Discussion 
HSPC is probably the most extensively studied somatic 
stem cell. It has the capability for self-renewal. It can also 
differentiate into all types of mature blood cells. Methods to 
expand HSPCs are always accompanied with their differen-
tiation. However, it is still difficult to obtain sufficient 
numbers of HSPCs for transplantation. For a broader clini-
cal application, additional studies are necessary for a deeper 
understanding of the cell biology of HSPCs, the microenvi-
ronment that nurtures these cells, and finding small mole-
cules that stimulate HSPC expansion.  
In this study, we found that a small molecule, CAPE, 
plays a regulatory role in HSPC in vitro proliferation. CAPE, 
a honeybee extract, exerts protective effect in I/R injury. It 
can minimize radiation-induced hearing damage in rats [20]. 
Moreover, CAPE has been found to be a protective agent 
against chemotherapy-induced and radiotherapy-induced 
toxicity [21]. Further study suggested that CAPE can induce 
the expression of HIF-1α protein and concomitantly trans- 
 
 
Figure 3  Survival rate analysis of MNCs growing for 7 d at different CAPE concentrations. The MNCs were stained with 7-AAD and Annexin V. Viable 
cells are in the lower left quadrant. 
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Figure 4  The CFU assays of CD34+ cells cultured for 7 d at different CAPE concentrations. A, The colony morphology of BFU-E, CFU-GM and 
CFU-GEMM. B, The colony numbers of BFU-E, CFU-G/GM/M and CFU-GEMM. C, The total CFU numbers were calculated. D, The HPP-CFU numbers 
were counted. CFU-GM: colony forming unit-granulocyte and macrophage; CFU-G/GM/M: colony forming unit-granulocyte/granulocyte and macro-
phage/megakaryocyte. *, P0.05; **, P0.01 vs. 0 μg mL1.  
 
Figure 5  Quantitative PCR analysis of the expression levels of prolifera-
tion and apoptosis-related genes in MNCs cultured for 7 days with differ-
ent concentrations of CAPE. *P0.05; **, P0.01 vs. 0 μg mL1. 
activate the HIF-1 target genes, such as vascular endothelial 
growth factor and heme oxygenase-1 (HO-1), which play a 
protective role in I/R injury [21]. By using gene chip analy-
sis, Wang reported that the expression levels of SCF and 
HO-1 genes were significantly upregulated in HUVECs. 
These genes play critical roles in HSPC proliferation and 
survival. Thus, we postulated that CAPE might function on 
HSPCs. We first evaluated its role on the survival of UCB 
MNCs. CAPE at low concentration levels (0.1 μg mL1 or 1 
μg mL1) showed little or slight effect on the survival rate of 
total nuclear cells. When the concentration of CAPE in me-
dium reached 5 μg mL1, it induced the reduction of the 
total cell numbers compared to the control group (data not 
shown). CAPE treatment at low concentration (0.1 μg mL1 
and 1 μg mL1) increased the numbers of CD34+ or 
CD34+CD38 cell in cultured UCB MNCs. The similar re-
sults were also seen in CFU assays (data not shown). These 
data suggested that CAPE might be used as a supplement in 
HSPC culture medium. We then isolated UCB CD34+ cells 
and cultured them in medium with cytokines plus CAPE at 
different concentrations. Similarly, low concentration of  
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CAPE (0.1 μg mL1) did not affect the apoptosis rate of 
cultured CD34+ cells. However, CAPE at 5 μg mL1 showed 
low cytotoxicity in cultured hematopoietic cells (data not 
shown). It has been reported that CAPE exerted the maxi-
mum cytoprotection in HUVECs against menadione-caused 
oxidative injury at 5 μg mL1 and it produced cytotoxicity at 
15 μg mL1 [10]. These data suggested that different kinds 
of cells responded to different levels of CAPE in different 
ways. On the other hand, CAPE might increase the survival 
rate of cultured CD34+ cells under stress. In a normal cul-
ture condition, CAPE-treated CD34+ cells exhibited in-
creased colony-forming capacity. Interestingly, BFU-E was 
the most obviously affected colony type, increasing more 
than 3.7-fold in cells treated with 1 μg mL1 CAPE com-
pared with the control group. We found that some genes 
(SCF, HIF-1α and HO-1) are significantly upregulated by 
CAPE in cultured UCB cells, which might be the mecha-
nism for CAPE to expand HSPCs. SCF, the most important 
cytokine for HSPC self-renewal, therefore is crucial to UCB 
HSPC expansion ex vivo. HIF-1α, a transcription factor, 
plays a pivotal role in cellular adaption to hypoxia. It has 
been reported that hypoxia and upregulation of HIF-1α ex-
pression enhanced the proliferation of UCB HSPCs in vitro 
[22]. HO-1, a target gene of HIF-1α, also exerts the im-
portant role in the regulation of HSPC function. However, 
more work need to be done to further evaluate the function 
of CAPE-treated HSPCs, especially under stress conditions. 
For example, Wang’s work showed that modification of the 
catechol ring of CAPE by introducing fluorine at various 
positions resulted in dramatic changes in cytoprotective 
activity [23]. Thus, it might be worth evaluating the role of 
CAPE derivatives on HSPC expansion under normal or 
stress culture condition. 
In conclusion, CAPE, the small molecule from honeybee 
extract, can promote HSPC expansion in vitro. The mecha-
nism of CAPE-induced HSPC expansion appears to involve 
upregulation of the expression of SCF, HIF-1α, and HO-1. 
Our data suggest that CAPE might become a new and po-
tent medium supplement for in vitro HSPC expansion. 
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